Unlike typical vaccines, ProscaVax is given to patients after a cancer diagnosis. The vaccine wraps cancer RNA in a fatty acid membrane and gives it a negative charge, alerting T cells to recognize and destroy the cancer cells.
Scientists believe they can tweak the vaccine to address any type of cancer.
So far, the study has only been conducted on three melanoma patients, but the data proves promising. Researchers have deemed the trial a success in demonstrating the safety of the vaccine, as side effects were limited to flu-like symptoms.
More articles on supply chain:
Tesaro’s ovarian cancer drug lengthens survival time in late-stage trial
FDA names Dr. Richard Padzur head of Cancer Moonshot’s Oncology Center of Excellence
Supreme Court maintains ruling to invalidate patent for prenatal test
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
